NCT05262764View on ClinicalTrials.gov

Post Marketing Surveillance (PMS) of JARDIANCE in Chronic Heart Failure (CHF)

CompletedOBSERVATIONAL
Enrollment

1,200

Participants

Timeline

Start Date

April 15, 2022

Primary Completion Date

June 21, 2024

Study Completion Date

June 28, 2024

Conditions
Heart Failure
Interventions
DRUG

JARDIANCE®

Treatment was in accordance with the latest guidelines from The Japanese Circulation Society (JCS).

Trial Locations (1)

1416017

Nippon Boehringer Ingelheim Co., Ltd., Tokyo

Sponsors
All Listed Sponsors
collaborator

Eli Lilly and Company

INDUSTRY

lead

Boehringer Ingelheim

INDUSTRY

NCT05262764 - Post Marketing Surveillance (PMS) of JARDIANCE in Chronic Heart Failure (CHF) | Biotech Hunter | Biotech Hunter